Month: August 2022

AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022 AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022 AFM24: Studies continue to enroll; data updates expected at scientific conferences in the second half of 2022 AFM28: Following interactions with FDA, strategic decision to focus early clinical development in non-U.S. jurisdictions; clinical study now expected to start in the first half of 2023 Cash and cash equivalents as of June 30, 2022 were approximately €237.2 million with anticipated cash runway into mid-2024 Conference call and webcast scheduled for August 11, 2022 at 8:30 a.m. EDT/14:30 CESTHEIDELBERG, Germany, Aug. 11, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq:...

—Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022– –The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will Receive Expedited Review– –European Medicines Agency’s Emergency Task Force Initiated Review of Sabizabulin Treatment for Hospitalized COVID Patients for Emergency Use in European Union Countries– –The New England Journal of Medicine Evidence® Published Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients– –Company Prepares for U.S. and Ex-U.S. Commercial Launches if Emergency Authorizations Are Granted– –Company to Host Investor Conference...

TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) — McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) today reported its second quarter (Q2) results for the period ended June 30th, 2022.Fox Complex performed well, producing 11,200 GEOs, the highest quarterly production in over three years, at cash costs of $985 per GEO and AISC of $1,290 per GEO.Average cash costs(2) per GEO sold from our 100%-owned mines in Q2 was $1,169, 15% below our guidance midpoint of $1,380 per GEO. Average all-in sustaining costs (“AISC“)(2) per GEO sold from our 100%-owned mines was $1,549, 11% below our guidance midpoint of $1,740 per GEO.Production was 27,600 gold ounces and 704,600 silver ounces, or 36,100 gold equivalent ounces(1) (GEOs)(see Table 1), compared to 40,700 GEOs during Q2 2021. San José mine delivered solid results producing 19,600 GEOs...

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility and Clarity on Phase 3 Program and Single Pivotal Registration Trial for MAT2203 in Cryptococcal Meningitis; Trial Expected to Commence Q1 2023 Initial Scientific Advice and Positive Opinion on Orphan Drug Designation from EMA Provide Global Regulatory Alignment for MAT2203 in Key Commercial Regions Company Remains in Discussions with BioNTech for Option to License the LNC Platform for mRNA on an Exclusive Basis $38.5 million at June 30, 2022, Sufficient to Fund Planned Operations Through 2023 Management to Host Conference Call Today, Thursday, August 11th, at 8:30 a.m. ET BEDMINSTER, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a...

– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the end of 2022 – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the second quarter ended June 30, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, August 11, 2022, at 8:30 a.m. ET (details below). Paula Brown Stafford, President and Chief Executive Officer of Novan commented, “In the first half of 2022, we have progressed Novan to a fully integrated medical dermatology company with capabilities spanning research and development...

– Quarterly Origination Volume of $9.3 Billion – – 3,573 Active Broker Partners in Second Quarter – – Second Quarter 2022 Net Loss of $(44.4) Million, or $(0.32) per Share – ANN ARBOR, Mich., Aug. 11, 2022 (GLOBE NEWSWIRE) — Home Point Capital Inc. (NASDAQ: HMPT) (together with its subsidiaries, “Home Point Capital” or the “Company”), the parent entity of Home Point Financial Corporation (“Homepoint”), today announced its financial results for the second quarter ended June 30, 2022. “We continued in the second quarter to focus on the key actions critical to navigating this cycle: further reducing expenses, enhancing our liquidity position and solely focusing on the origination channel that is best for consumers – wholesale,” said Willie Newman, President and Chief Executive Officer. “We were successful in our efforts to further...

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022. “We have reset our thesis and executed on several critical milestones in the first half of 2022. On July 18th, we announced the submission of our proposed registrational protocol for EB613 to the U.S. Food and Drug Administration (FDA). We are simultaneously finalizing the validation of an optimized formulation of EB612, while expanding our pre-clinical pipeline with additional anti-inflammatory and metabolic protein candidates. Lastly, we finished the quarter with $17.3 million in cash which, given our revised Phase 3 schedule, is projected to fund our current...

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — Outbrain Inc. (Nasdaq: OB), a leading recommendation platform for the open web, announced today financial results for the quarter ended June 30, 2022. “We are pleased to report that despite worsening macroeconomic headwinds, we delivered on the guidance we provided for the second quarter of 2022,” said David Kostman, Outbrain’s Co-CEO. “We continued to gain significant market share globally with wins of top premium publishers throughout 2022. We expect that this increased market share, together with our investments in technology and product, will position us well for strong growth when the advertising market recovers. Nevertheless, in view of market softness and economic uncertainty, we continued to adjust our cost structure with focus on profitability.” “Product innovation, quality,...

Completed Business Combination Between Lionheart Acquisition Corporation II and MSP RecoveryPaid Value of Potentially Recoverable Claims Grew to $88.3 Billion During QuarterAcquired Claim Recovery Rights and Rights to Cash Flows Increasing Balance Sheet Assets from $104 Million at December 31, 2021 to $6.6 Billion at June 30, 2022Executed Agreements which could provide approximately $1.5 Billion of Capital CORAL GABLES, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) — MSP Recovery, Inc. (NASDAQ: MSPR) (“MSPR,” “MSP Recovery,” or the “Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, today announced financial results for the second quarter ended June 30, 2022. MSPR has seen substantial growth of assets from $104 million at December 31, 2021 to...

WILLIAMSBURG, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the second quarter ended June 30, 2022. The Company’s results include the following*:  Three Months Ended     Six Months Ended    June 30, 2022     June 30, 2021     June 30, 2019     June 30, 2022     June 30, 2021     June 30, 2019    ($ in thousands except per share data)     ($ in thousands except per share data)  Total revenue $ 47,170     $ 34,383     $ 51,541     $ 85,523     $ 57,019     $ 98,931  Net income (loss) attributable to common stockholders   24,269       (2,811 )     (732 )     21,762       (11,876 )     (2,385 )                                   EBITDA   8,018       8,930       12,037       17,441       12,220       23,195  Hotel...